search
Back to results

Individual Determinants of Postprandial Glucose Response in Type 2 Diabetes (DIABEST)

Primary Purpose

Type 2 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Test meal with postprandial samples
Sponsored by
Federico II University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Post-prandial glucose response, Personalized nutrition, Personalized therapeutic strategies, Continuous glucose monitoring, Gut microbiota

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Men and post-menopausal women HbA1c ≤ 7.5% Body Mass Index (BMI) 20-39.9 kg/m2 Ability to comply with the study protocol activities. Exclusion Criteria: Any acute or chronic condition possibly influencing the interpretation of the results or possibly worsened because of study participation Pregnancy or breast-feeding Use of antibiotics, probiotics, or prebiotics during the last three months.

Sites / Locations

  • Department of Clinical Medicine and Surgery Federico II UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Men and post-menopausal women with type 2 diabetes on treatment with diet or diet plus metformin

Arm Description

Each participant will undergo anthropometrics and blood pressure measurements, bioimpedance analysis, indirect calorimetry, administrations of questionnaires for the evaluation of lifestyle habits, 7 days continuous glucose monitoring in parallel with diet, physical activity and sleep monitoring, and standard mixed-nutrient meals at home; a subgroup of 60 participants will undergo venous blood sampling for biochemical determinations before and after a standard mixed-nutrient meal.

Outcomes

Primary Outcome Measures

Post-prandial glucose response
Post-prandial glucose response will be calculated by the trapezoidal method as the area under the curve above the baseline value (iAUC).

Secondary Outcome Measures

Energy intake
The energy intake expressed in kilocalories and derived by the analysis of the 7-day food record plus the European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaire will be evaluated in relation to the post-prandial glucose response (iAUC).
Dietary components
The dietary components, namely available carbohydrates, total proteins, animal proteins, plant proteins, total fats, saturated fats, mono- and polyunsaturated fats, fibre and sugars (all expressed in grams), will be derived by the analysis of the 7-day food record and the (European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaire, and evaluated in relation to the to the post-prandial glucose response (iAUC).
Gut-microbiota composition
Gut microbiota composition will be assessed using relative bacterial taxonomic abundances and measures of community diversity and richness (derived from 16 S ribosomal ribonucleic acid (rRNA) high-throughput sequencing of baseline stool specimens), and will be evaluated in relation to the post-prandial glucose response (iAUC).
Physical activity levels
Physical activity levels as detected by the ActiGraph device (GT3X+ActiGraph LLC, Pensacola, Florida; sampling frequency: 30 Hz) worn for 7 days on the non-dominant wrist, and expressed as % of time spent in sedentary-light-moderate activity will be evaluated in relation to the post-prandial glucose response (iAUC).
Sleep duration
Sleep metrics, namely total sleep time, sleep onset latency, wake after sleep onset (all measured in minutes), as detected by ActiGraph device worn for 7 days and nights and calculated by the software (ActiGraph LLC, Pensacola, Florida; version 6.13.4), will be evaluated in relation to the post-prandial glucose response (iAUC).

Full Information

First Posted
July 19, 2023
Last Updated
October 8, 2023
Sponsor
Federico II University
search

1. Study Identification

Unique Protocol Identification Number
NCT06057246
Brief Title
Individual Determinants of Postprandial Glucose Response in Type 2 Diabetes
Acronym
DIABEST
Official Title
Exploring Individual Determinants of postpranDIAl Glucose Response in Type 2 diaBEteS to opTimize Therapeutic Strategies With a Personalized Approach (DIABEST)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 15, 2023 (Actual)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
May 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federico II University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Postprandial glycemia (PPG) is a relevant determinant of glucose control in people with type 2 diabetes (T2D). Epidemiological and pathophysiological studies indicate that PPG is a better risk predictor for cardiovascular disease and all-cause mortality than fasting plasma glucose. Therefore, both fasting and postprandial glycemia should be targeted to achieve optimal glycemic control and, thus, prevent or reduce the risk of diabetes complications. Post-prandial glucose response (PGR) cannot be predicted based solely on the meals' carbohydrate content. Recent research using continuous glucose monitoring (CGM) systems has identified different patterns of PGR to a standard meal among both healthy people and individuals with type 1 diabetes. Different contributors to the PGR have emerged, including genotype, hormonal and metabolic factors, phenotype, gut microbiota composition, background diet, sleep habits, physical activity levels. The present project aims at exploring the PGR in a real-life setting in a cohort of people with T2D, and identifying person-specific factors associated with different postprandial glucose patterns. To this purpose, 144 individuals with T2D on treatment with diet alone or diet plus metformin will be characterized for their anthropometric, metabolic, and gut-microbiome features and will undergo a one-week observational period through CGM system, while properly recording their food intake, physical activity, and sleep habits. A mixed-nutrient standardized meal will be consumed at home in two occasions by each participant to investigate the intra-individual variability of the PGR. Moreover, in a subgroup of participants (n=60), divided according to anthropometric and metabolic features, hormonal and metabolic response to the standardized meal will be evaluated at the hospital, to explore the contribution of different T2D phenotypes to the PGR. A further step will be developing a prediction algorithm of PGR based on the intra- and inter-individual factors shown to influence postprandial glucose, able to further optimize the management of T2D with precision therapeutic strategies.
Detailed Description
The participants will undergo a 7-day observational period and acute postprandial tests with a standardized meal. Before the study initiation, all participants will undergo a screening visit for the assessment of inclusion and exclusion criteria. Participants meeting the inclusion criteria will be instructed to collect a stool sample and will be scheduled for the experimental visit (day 0). At day 0, each participant will arrive at the diabetes clinic in the morning, after a 10-hour fasting, to undergo: venous blood sampling for biochemical determinations anthropometrics and blood pressure measurements body composition evaluation (bioimpedance analysis) basal metabolic rate evaluation (indirect calorimetry) administrations of questionnaires for the evaluation of lifestyle habits positioning of a subcutaneous sensor for continuous glucose monitoring (CGM). Information regarding characteristics of bowel movements in the day of stool sampling will be collected according to the Bristol stool scale. The participants will be instructed to consume at home a mixed-nutrient meal at breakfast on the second day and on the last day of the observational period. PGR will be assessed by CGM. Over the following 7 days, participants will undergo CGM while keeping stable their own dietary and lifestyle habits and will be asked to record the following information by using a dedicated app: a 7-day food diary reporting all foods and drinks consumed, including dressing, portions by household measures (cup, spoons, etc.) or weight, and providing as much details as possible (i.e., cooking methods, brands names). Seven-day food records will be discussed with a skilled dietitian to check potential mistakes and missing information. Energy intake and dietary composition (nutrients and non-nutrients), and food groups consumption will be calculated using the Food Composition Database for epidemiological Studies in Italy of the European Institute of Oncology; any stressful event or drug assumption. In parallel, during the 7-day observational period, data on physical activity levels and sleep habits will be collected by using an accelerometer (Actigraph medical device). At the 8th day, a subgroup of 60 participants (20 with prevalent impairment of insulin sensitivity, 20 with prevalent impairment of insulin secretion, and 20 with prevalent visceral obesity - as determined by anthropometrics, fasting C-peptide, and plasma triglycerides) will return to the hospital and consume the same standardized meal consumed at home. Before and over 4 hours after the meal, venous blood samples will be collected at fixed time points for biochemical evaluations. CGM data from 30 min before meal to 6 h after meal will be analyzed. Postprandial blood glucose changes will be calculated with the trapezoidal method as the incremental area under the curve above the baseline value (iAUC). Predictors of early blood glucose response (iAUC0-3h), late blood glucose response (iAUC3-6h), total blood glucose response (iAUC0-6h), and, as indicator of time-course of the blood glucose changes, the difference between late and early response (iAUC3-6h minus 0-3h) will be evaluated using mixed-effect linear regression considering the patient's identification number (ID) as a random effect. To evaluate the significance of the random-effect factor, ANOVA will be used to test for the difference between the model with and without the random effect.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Post-prandial glucose response, Personalized nutrition, Personalized therapeutic strategies, Continuous glucose monitoring, Gut microbiota

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
144 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Men and post-menopausal women with type 2 diabetes on treatment with diet or diet plus metformin
Arm Type
Experimental
Arm Description
Each participant will undergo anthropometrics and blood pressure measurements, bioimpedance analysis, indirect calorimetry, administrations of questionnaires for the evaluation of lifestyle habits, 7 days continuous glucose monitoring in parallel with diet, physical activity and sleep monitoring, and standard mixed-nutrient meals at home; a subgroup of 60 participants will undergo venous blood sampling for biochemical determinations before and after a standard mixed-nutrient meal.
Intervention Type
Other
Intervention Name(s)
Test meal with postprandial samples
Intervention Description
The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, air-cured beef, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.
Primary Outcome Measure Information:
Title
Post-prandial glucose response
Description
Post-prandial glucose response will be calculated by the trapezoidal method as the area under the curve above the baseline value (iAUC).
Time Frame
7 days (related to the 7-day continuous glucose monitoring)
Secondary Outcome Measure Information:
Title
Energy intake
Description
The energy intake expressed in kilocalories and derived by the analysis of the 7-day food record plus the European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaire will be evaluated in relation to the post-prandial glucose response (iAUC).
Time Frame
7 days (related to the 7-day continuous glucose monitoring and food record)
Title
Dietary components
Description
The dietary components, namely available carbohydrates, total proteins, animal proteins, plant proteins, total fats, saturated fats, mono- and polyunsaturated fats, fibre and sugars (all expressed in grams), will be derived by the analysis of the 7-day food record and the (European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaire, and evaluated in relation to the to the post-prandial glucose response (iAUC).
Time Frame
7 days (related to the 7-day continuous glucose monitoring and food record)
Title
Gut-microbiota composition
Description
Gut microbiota composition will be assessed using relative bacterial taxonomic abundances and measures of community diversity and richness (derived from 16 S ribosomal ribonucleic acid (rRNA) high-throughput sequencing of baseline stool specimens), and will be evaluated in relation to the post-prandial glucose response (iAUC).
Time Frame
7 days (related to the 7-day continuous glucose monitoring)
Title
Physical activity levels
Description
Physical activity levels as detected by the ActiGraph device (GT3X+ActiGraph LLC, Pensacola, Florida; sampling frequency: 30 Hz) worn for 7 days on the non-dominant wrist, and expressed as % of time spent in sedentary-light-moderate activity will be evaluated in relation to the post-prandial glucose response (iAUC).
Time Frame
7 days (related to the 7-day continuous glucose and physical activity monitoring)
Title
Sleep duration
Description
Sleep metrics, namely total sleep time, sleep onset latency, wake after sleep onset (all measured in minutes), as detected by ActiGraph device worn for 7 days and nights and calculated by the software (ActiGraph LLC, Pensacola, Florida; version 6.13.4), will be evaluated in relation to the post-prandial glucose response (iAUC).
Time Frame
7 days (related to the 7-day continuous glucose and sleep monitoring)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and post-menopausal women HbA1c ≤ 7.5% Body Mass Index (BMI) 20-39.9 kg/m2 Ability to comply with the study protocol activities. Exclusion Criteria: Any acute or chronic condition possibly influencing the interpretation of the results or possibly worsened because of study participation Pregnancy or breast-feeding Use of antibiotics, probiotics, or prebiotics during the last three months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Angela A Rivellese, Professor
Phone
00390817463665
Email
rivelles@unina.it
Facility Information:
Facility Name
Department of Clinical Medicine and Surgery Federico II University
City
Naples
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angela A Rivellese, Professor
Phone
00397473665

12. IPD Sharing Statement

Citations:
PubMed Identifier
30040822
Citation
Hall H, Perelman D, Breschi A, Limcaoco P, Kellogg R, McLaughlin T, Snyder M. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol. 2018 Jul 24;16(7):e2005143. doi: 10.1371/journal.pbio.2005143. eCollection 2018 Jul.
Results Reference
result
PubMed Identifier
34711639
Citation
Shilo S, Godneva A, Rachmiel M, Korem T, Kolobkov D, Karady T, Bar N, Wolf BC, Glantz-Gashai Y, Cohen M, Zuckerman Levin N, Shehadeh N, Gruber N, Levran N, Koren S, Weinberger A, Pinhas-Hamiel O, Segal E. Prediction of Personal Glycemic Responses to Food for Individuals With Type 1 Diabetes Through Integration of Clinical and Microbial Data. Diabetes Care. 2022 Mar 1;45(3):502-511. doi: 10.2337/dc21-1048.
Results Reference
result
PubMed Identifier
36122866
Citation
Bozzetto L, Pacella D, Cavagnuolo L, Capuano M, Corrado A, Scida G, Costabile G, Rivellese AA, Annuzzi G. Postprandial glucose variability in type 1 diabetes: The individual matters beyond the meal. Diabetes Res Clin Pract. 2022 Oct;192:110089. doi: 10.1016/j.diabres.2022.110089. Epub 2022 Sep 17.
Results Reference
result
PubMed Identifier
26590418
Citation
Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalova L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001.
Results Reference
result
PubMed Identifier
32528151
Citation
Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, Capdevila J, Hadjigeorgiou G, Davies R, Al Khatib H, Bonnett C, Ganesh S, Bakker E, Hart D, Mangino M, Merino J, Linenberg I, Wyatt P, Ordovas JM, Gardner CD, Delahanty LM, Chan AT, Segata N, Franks PW, Spector TD. Human postprandial responses to food and potential for precision nutrition. Nat Med. 2020 Jun;26(6):964-973. doi: 10.1038/s41591-020-0934-0. Epub 2020 Jun 11. Erratum In: Nat Med. 2020 Nov;26(11):1802.
Results Reference
result

Learn more about this trial

Individual Determinants of Postprandial Glucose Response in Type 2 Diabetes

We'll reach out to this number within 24 hrs